McKesson (NYSE:MCK) EVP Sells 650 Shares of Company Stock

Key Points

• EVP Francisco Fraga sold 650 McKesson shares for about $716,924, reducing his direct holdings by 12.84% to 4,414 shares. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
• McKesson beat quarterly expectations, reporting adjusted EPS of $11.68 versus $10.72 expected and revenue of about $111 billion, up 7.5% year over year.
• Analysts hold a consensus “Moderate Buy” rating, with a reported average price target of $1,026.18; the stock traded at $1,064.72 in Friday’s session.

McKesson Corporation (NYSE:MCK - Get Free Report) EVP Francisco Fraga sold 650 shares of McKesson stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $1,102.96, for a total transaction of $716,924.00. Following the transaction, the executive vice president directly owned 4,414 shares of the company's stock, valued at approximately $4,868,465.44. This represents a 12.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Francisco Fraga also recently made the following trade(s):

• On Wednesday, November 4th, Francisco Fraga sold 600 shares of McKesson stock. The shares were sold at an average price of $1,050.00, for a total transaction of $630,000.00.
• On Thursday, October 15th, Francisco Fraga sold 800 shares of McKesson stock. The stock was sold at an average price of $995.80, for a total transaction of $796,640.00.

McKesson Stock Performance

NYSE MCK traded down $7.28 during trading on Friday, hitting $1,064.72. The stock had a trading volume of 314,474 shares, compared to its average volume of 917,154. The stock has a market capitalization of $124.14 billion, a price-to-earnings ratio of 27.40, a P/E/G ratio of 2.13 and a beta of 0.27. McKesson Corporation has a one year low of $723.68 and a one year high of $1,121.50. The stock has a 50 day simple moving average of $934.72 and a 200 day simple moving average of $866.92.

McKesson (NYSE:MCK - Get Free Report) last announced its earnings results on Wednesday, November 4th. The company reported $11.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.72 by $0.96. The business had revenue of $110.96 billion during the quarter, compared to analyst estimates of $109.90 billion. McKesson had a negative return on equity of 235.48% and a net margin of 1.12%. The company's revenue for the quarter was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $9.86 earnings per share. On average, sell-side analysts predict that McKesson Corporation will post 44.71 EPS for the current year.

McKesson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, January 4th. Investors of record on Tuesday, December 1st will be paid a $0.94 dividend. The ex-dividend date of this dividend is Tuesday, December 1st. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. McKesson's dividend payout ratio is 9.67%.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on MCK. Morgan Stanley set a $977.00 price target on shares of McKesson in a report on Tuesday, October 6th. Royal Bank Of Canada increased their price objective on shares of McKesson from $845.00 to $965.00 and gave the company a "sector perform" rating in a research note on Thursday. Bank of America lifted their price objective on shares of McKesson from $950.00 to $1,050.00 in a report on Thursday, August 6th. Leerink Partners boosted their price objective on shares of McKesson from $1,070.00 to $1,200.00 and gave the stock an "outperform" rating in a research note on Thursday. Finally, Wall Street Zen upgraded McKesson from a "hold" rating to a "buy" rating in a report on Saturday, October 17th. Fifteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $1,026.18.

Trending Headlines about McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Fiscal Q2 2027 adjusted EPS of $11.68 and revenue of about $111 billion beat estimates. McKesson also raised its fiscal 2027 adjusted EPS outlook to $45.60–$46.40, citing specialty-drug demand, higher prescription volumes and operating gains. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
• Positive Sentiment: UBS raised its price target to $1,250 and kept a Buy rating. Other firms, including TD Cowen and Leerink Partners, set targets of $1,200, reflecting optimism about execution and growth prospects. McKesson Hits a 52-Week High
• Neutral Sentiment: McKesson completed its $2.25 billion Precision Medicine Group acquisition, expanding its healthcare services presence; the longer-term financial contribution remains to be seen. McKesson Outlines Fiscal 2027 EPS and Precision Medicine Deal
• Neutral Sentiment: EVP Francisco Fraga sold 600 shares under a pre-arranged plan to cover tax withholding on vested equity awards, limiting the significance of the sale as a signal about his outlook. SEC Filing
• Negative Sentiment: RBC’s “sector perform” rating and $965 target are below the recent share price, signaling that at least one analyst sees limited upside after the stock’s strong advance. RBC on McKesson’s Execution

Institutional Trading of McKesson

Several hedge funds have recently modified their holdings of the company. Nvwm LLC lifted its stake in shares of McKesson by 933.3% in the 3rd quarter. Nvwm LLC now owns 31 shares of the company's stock worth $26,000 after acquiring an additional 28 shares during the period. Delos Wealth Advisors LLC acquired a new position in shares of McKesson during the second quarter worth about $27,000. Trellis Wealth Advisors LLC acquired a new position in shares of McKesson during the third quarter worth about $32,000. Clearstead Trust LLC acquired a new position in shares of McKesson during the second quarter worth about $37,000. Finally, GK Wealth Management LLC acquired a new position in McKesson during the 3rd quarter worth approximately $38,000. 85.07% of the stock is owned by hedge funds and other institutional investors.

McKesson Company Profile

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and other medical products. Its customers include pharmacies, hospitals, health systems, clinics and other healthcare providers.

The company also provides medical-surgical supplies and technology and services that support pharmacy operations, prescription management and care delivery. Its offerings include specialized support for oncology and other areas of care.

Founded in 1833, McKesson serves customers primarily in the United States and Canada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.